Treatment of multiple myeloma with a combination of panobinostat and bortezomib at specified doses adjusted for safety.

The present invention relates to a method of screening for a cancer selected from the group consisting of prostate cancer, thyroid cancer, colon cancer, rectum cancer, lung cancer, uterine cancer, breast cancer, pancreatic cancer, bladder cancer, liver cancer, bile duct cancer, stomach cancer, oesophageal cancer, head and neck cancer, brain cancer, blood cancer, ovarian cancer, skin cancer, melanoma and a neuroendocrine tumour in a subject, said method comprising determining the level and/or chemical composition of one or more of the glycosaminoglycans (GAGs) chondroitin sulfate (CS), heparan sulfate (HS), and hyaluronic acid (HA) in a body fluid sample, wherein said sample has been obtained from said subject.

The present invention relates to: a method for providing information for the prediction or diagnosis of oral precancer or oral cancer characterized by confirming expression of the Axin2 gene or the Snail gene in an oral leukoplakia tissue sample or an oral submucous fibrosis tissue sample; and a use of a compound capable of delaying or inhibiting the progression of a precancerous lesion and recurrent oral cancer using the compound capable of effectively inhibiting the expression of the Axin2 gene or the Snail gene. According to the present invention, the possibility of oral leukoplakia or submucous fibrosis which causes white lesions to appear inside the oral cavity can be predicted and diagnosed, thereby being useful in eliminating the potential risks of oral cancer by early prediction of progression into oral precancer or oral cancer for which effective treatment does not currently exist.

A method of identifying cancer patients who would be responsive to bladder sparing surgery plus chemoradiation therapy or cystectomy using expression of MRE11 in a nuclear to cytoplasmic ratio is presented.

A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analysing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT. Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT.

Tumor invasion and metastasis is accompanied by significant activations of specific proteolysis enzymes. Tumor area is known to have increased infiltration of immunoglobulins G (IgG), so IgG may undergo proteolysis in this area. Serine proteases usually cleave peptide bonds between positively charged amino acids lysine and arginine. Since the intact PLG molecules as well as its fragments have lysine binding sites, they can bind to damaged IgG or fragments thereof with free C-terminal lysine that can appear in a circulation after proteolysis in the malignant tumor area. In the present invention we demonstrated the increased binding of damaged IgG or fragments thereof with free C-terminal lysine to fragments of PLG in samples from patients with breast cancer, ovarian cancer, lung cancer, colorectal cancer, prostate cancer vs. samples from healthy donors, and thus we proposed a novel diagnostic method.

Disclosed are bladder cancer protein biomarkers, methods of determining whether a patient suffers from or shows recurrence of bladder cancer or early stage bladder cancer, or late stage bladder cancer using the bladder cancer protein biomarkers, a detection system, and kits thereof. Said bladder cancer biomarkers comprise at least one of Coronin-IA, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1, and variants thereof.

Provided herein are methods for selecting/identifying and/or isolating cancer stem cells from a biological sample or a cell culture sample using a fluorescent glucose analog. Also provided herein are methods for selecting/identifying and/or isolating leukemia stem cells and subpopulations thereof. The present invention is based, in part, on the discovery that cancer stem cells can be selected/identified based upon a lower level of fluorescence of the fluorescent glucose analog compared to non-cancer stem cells and that specific genes are differentially expressed in leukemia stem cells compared to non-leukemia stem cells.

Provided herein are methods, kits, systems, and compositions or liquid biopsy yield enhancement.

The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.